anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Preventing Atherosclerotic Cardiovascular Diseases (ASCVD) can best be achieved by promoting a healthy lifestyle through improvements in diet, physical activity, and avoidance of tobacco use and exposure to second-hand smoke. The study aimed to determine the association between physical activity as well as obesity and the risk of atherosclerotic cardiovascular diseases among patients with hypertension and diabetes attending Irrua Specialist Teaching Hospital (ISTH), Irrua, Nigeria.
METHODOLOGY: The research was a descriptive, cross-sectional study of 394 systematically selected consenting patients with hypertension and diabetes presenting to a teaching hospital in Irrua, Edo State, Nigeria. The Cardiovascular risk assessment was determined using the Framingham 10year Risk of General Cardiovascular Disease. Anthropometric assessment, blood pressure and blood glucose were determined. Data was collected with a semi-structured questionnaire and analysed with Stata version 16. Chi square and logistic regression was used to test for association and significance level was set at p = 0.05.
RESULTS: The study included 394 participants with a mean age of 54±15.47years. Respondents were mostly females (55.3%), physically inactive (70.3%), overweight (42.4%) and had a high risk (41.8%) of developing CVD in 10 years using Framingham categorisation. There was a significant association between physical activity (P<0.01; OR 2.45; CI: 1.53-3.92), obesity (P<0.01; OR 2.52; CI: 1.64-3.86) and risk of developing CVD.
CONCLUSION: The study found a statistically significant relationship between physical inactivity, obesity, and the risk of atherosclerotic cardiovascular diseases. Increasing physical activity levels need to be a top priority at all levels of healthcare as well as the general population.
BACKGROUND: Mobile health (mHealth) has become an increasingly popular strategy to improve healthcare delivery and health outcomes. Communicating results and health education via text may facilitate program planning and promote better engagement in care for women undergoing human papillomavirus (HPV) screening. We sought to develop and evaluate an mHealth strategy with enhanced text messaging to improve follow-up throughout the cervical cancer screening cascade.
METHODS: Women aged 25-65 participated in HPV testing in six community health campaigns (CHCs) in western Kenya as part of a single arm of a cluster-randomized trial. Women received their HPV results via text message, phone call, or home visit. Those who opted for text in the first four communities received "standard" texts. After completing the fourth CHC, we conducted two semi-structured focus group discussions with women to develop an "enhanced" text strategy, including modifying the content, number, and timing of texts, for the subsequent two communities. We compared the overall receipt of results and follow-up for treatment evaluation among women in standard and enhanced text groups.
RESULTS: Among 2368 women who were screened in the first four communities, 566 (23.9%) received results via text, 1170 (49.4%) via phone call, and 632 (26.7%) via home visit. In the communities where enhanced text notification was offered, 264 of the 935 screened women (28.2%) opted for text, 474 (51.2%) opted for phone call, and 192 (20.5%) for home visit. Among 555 women (16.8%) who tested HPV-positive, 257 (46.3%) accessed treatment, with no difference in treatment uptake between the standard text group (48/90, 53.3%) and the enhanced text group (22/41, 53.7%). More women in the enhanced text group had prior cervical cancer screening (25.8% vs. 18.4%; p < 0.05) and reported living with HIV (32.6% vs. 20.2%; p < 0.001) than those in the standard text group.
CONCLUSIONS: Modifying the content and number of texts as an enhanced text messaging strategy was not sufficient to increase follow-up in an HPV-based cervical cancer screening program in western Kenya. A one-size approach to mHealth delivery does not meet the needs of all women in this region. More comprehensive programs are needed to improve linkage to care to further reduce structural and logistical barriers to cervical cancer treatment.
The invention relates to the use of bisphosphonic acids and the derivatives thereof for producing medicaments for preventing and treating autoimmune diseases or allergies combined with the autoantigens specifically used for treating the respective autoimmune disease or combined with the allergens specificall y used for treating the respective allergy. Some examples of the bisphosphonic acids or derivatives thereof which are us ed according to the invention include amino-hydroxy-methylidene-bisphosphonic acid (AMP), 2-amino-1- hydroxyethylidene-1,1-bisphosphonic acid (AEP), pamidronic acid, alendronic acid, 2-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AEP), amidinomethylene-bisphosphonic acid (AEP), ibandronic acid. risedronic acid, zoledronic acid, cimadronic acid, and tiludronic acid. Some examples of autoimmune diseases in which bisphosphonic acids or the derivatives thereof can be used include rheumatoi d arthritis, severe myasthenia, diabetes mellitus, uveitis, and scleroderma. The bisphosphonic acids or the derivatives thereof and the autoantigens or allergens can be applied simultaneously or in succession. The preparations of the combinations can be used in solid form, as ointments, as solutions or as sprays.
PROBLEM TO BE SOLVED: To efficiently and uniformly contact binder liquid with powder by supplying the binder liquid frozen and formed into fine particles in a method for granulating the powder while supplying the binder liquid. SOLUTION: As the binder liquid, water, so called solution prepared by dissolving the powder to be granulated in water, the one prepared by dissolving a binder in water or a solvent, or the like, is used and water or the solution is preferable. The particle diameter of the frozen fine particle, which has a specific relation to the particle diameter of the granulated product, is adjusted correspondingly to a required particle diameter of the product and is preferably 30-250 μm. The frozen finely particulate binder is preferably supplied to the powder at a low temp. The powder is kept at a low temp. to prevent the melting of the supplied frozen particle before being sufficiently mixed and dispersed and the temp. is preferably kept at -10 deg.C to 20 deg.C.  As the granulating method, a fluidized bed granulating method or a stirring granulating method, which has excellent mixing property for solid particle, is desirable.
Multisystem inflammatory syndrome in children (MIS-C) is a known complication of COVID-19. There is still limited knowledge about this condition. Here, we report the case of a previously healthy toddler boy, who presented with acute liver failure and duodenal lesions resulting in severe haematemesis and haemorrhagic shock, requiring intensive care unit care. The patient had persistent transaminitis, a deranged coagulation profile, inflammatory markers were elevated, and laboratory tests were negative for common infectious hepatitis aetiologies as well as COVID-19 Reverse transcription polymerase chain reaction. His COVID-19 antibody was reactive. Upper gastrointestinal endoscopy revealed a Forrest grade III duodenal ulcer. Looking into the constellation of symptoms and laboratory findings a confirmed diagnosis of acute viral hepatitis caused by MIS-C was made. Hence, he was given intravenous methylprednisolone along with intravenous immunoglobulins, after which he improved clinically and transaminitis resolved. The patient was discharged on clinical improvement and was doing fine on follow-up up to 6 months.
There is evidence of the impact of chrononutrition on weight loss and metabolic control. However, the precise chrononutrition behaviours that promote these benefits are not fully described, and there are doubts if chrononutrition may be related to other eating behaviour features. The main aim was to evaluate the associations between chrononutrition and eating behaviour, and their relationships with anthropometric and biochemical parameters among obese patients elected for bariatric surgery. Eighty participants (76.3% females, mean age = 45 years, mean BMI = 41.6 kg/m2) attending bariatric surgery consultations at Centro Hospitalar Universitário de São João (Porto, Portugal) were assessed regarding chrononutrition (Chrononutrition Profile - Questionnaire) and eating behaviour (Three-Factor Eating Questionnaire - R21 and General Eating Self-Efficacy Scale). Height, weight, waist circumference, and biochemical values (total, HDL and LDL cholesterol, triglycerides and glycated haemoglobin) were collected. Eating window midpoint was positively correlated with uncontrolled eating and negatively with eating self-efficacy. Sleep duration and midpoint on free days negatively correlated with eating self-efficacy, mainly due to later waking times, supporting that predominantly later energy consumption may negatively impact eating behaviour.
One rumen-fistulated Holstein-Friesian dairy cow in high lactation status will be given 0.6 L deuteriated water 3 times per day for 3 days long. Milk collection will take place twice a day on the fourth and fifth day. Milk will be processed into skimmed milk powder.
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
Terminology in schistosomiasis is not harmonised, generating misunderstanding in data interpretation and clinical descriptions. This study aimed to achieve consensus on definitions of clinical aspects of schistosomiasis in migrants and returning travellers. We applied the Delphi method. Experts from institutions affiliated with GeoSentinel and TropNet, identified through clinical and scientific criteria, were invited to participate. Five external reviewers revised and pilot-tested the statements. Statements focusing on the definitions of acute or chronic; possible, probable, or confirmed; active; and complicated schistosomiasis were managed through REDCap and replies managed in a blinded manner. Round 1 mapped the definitions used by experts; subsequent rounds were done to reach consensus, or quantify disagreement, on the proposed statements. Data were analysed with percentages, medians, and IQRs of a 5-point Likert scale. The study was terminated on the basis of consensus or stability-related and time-related criteria. 28 clinicians and scientists met the criteria for experts. 25 (89%) of 28 experts replied to Round 1, 18 (64%) of 28 to Round 2, 19 (68%) of 28 to Round 3, and 21 (75%) of 28 to at least two rounds. High-level consensus (79-100% agreement and IQRs ≤1) was reached for all definitions. Consensus definitions will foster harmonised scientific and clinical communication and support future research and development of management guidelines for schistosomiasis.
The invention discloses a preparation method for Mongolian four-species elecampane inula root decoction superfine powder tablets, granules and capsules. A superfine grinding technology adopted the four-species elecampane inula root decoction superfine powder is based on the theory of breaking plant medicine cell walls and promoting dissolution and dispersion of ingredients in cells, and the dissolving-out quantity and speed of the ingredients in the plant cells in vivo or a solvent are increased to achieve the aims of improving the bioavailability of medicine, reducing the taking amount and improving preparation quality. Processes adopted in the four-species elecampane inula root decoction granules comprise the freeze-drying process, the beta-cyclodextrin inclusion process and the coating process. Effective ingredients are fully kept, and meanwhile the problems that the taste is poor, carrying is inconvenient, and taking is inconvenient are solved. Processes adopted in the four-species elecampane inula root decoction capsules comprise the freeze-drying process, the beta-cyclodextrin inclusion process and the capsule preparation process. The effective ingredients are fully kept, the defects of solid dosage forms are overcome, the bioavailability is improved, and meanwhile the problem that the taste is poor and other problems are solved.
INTRODUCTION: Stroke survivors usually present physical and neuropsychiatric complications. Post-stroke psychosis (PSPsy) is a particularly neglected sequel despite its disruptive nature.
OBJECTIVES: To present a case of early emerging neuropsychiatric symptoms following a left posterior cerebral artery (PCA) stroke. To review and discuss PSPsy clinical manifestations, pathophysiology, and clinical outcomes.
CLINICAL CASE: A previously autonomous 68-year-old woman with vascular risk factors and depressive disorder presented to the emergency department with a 5-day history of disorientation, motor aphasia, and right hypoesthesia. Computer tomography revealed a left PCA stroke. She was started on acetylsalicylic acid and rosuvastatin and discharged the next day. Afterward, the patient developed a depressive mood, emotional lability, periods of confusion, delusions of persecution, guilt and unworthiness, auditory hallucinations, and suicide ideation. She was admitted to a psychiatric hospital and started on risperidone with a good response, being discharged after 15 days with the resolution of psychiatric symptoms.
CONCLUSIONS: PSPsy is more common after right hemisphere lesions and usually develops after some months. Nevertheless, our patient presented PSPsy following an ischemic event of the left PCA, with neuropsychiatric symptomatology dominating the clinic since the beginning. The involvement of the retrosplenial cortex or its connections was likely important for this atypical presentation. Due to the lack of guidelines on approaching PSPsy, most patients are treated with the same strategies used for non-stroke patients. A better comprehension of the anatomical basis underlining the symptomatology in these patients could deepen the understanding of psychosis and psychotic disorders.
Provided herein relates to self-assembling peptides and various nanostructures self-assembled from the isolated peptides. In some embodiments, the self-assembling peptides can form a nanostructure, e.g., a nanoparticle or microparticle, for use in various biomedical applications such as drug delivery or tissue engineering. In some embodiments, the nanostructures can comprise an agent, e.g., a biological molecule. The agent can be encapsulated or entrapped in the nanostructures during formation of the nanostructures. Alternatively or additionally, the agent can be integrated directly or indirectly (e.g., via a linker or a conjugation or crosslinking agent) to the self-assembling peptide structure, prior to formation of the nanostructures. In some embodiments where the agent is a peptide-based agent, unitary peptide nano structures, rather than nanoparticles that are formed and later covalently modified, can be generated.
Fludarabine is a potent antineoplastic agent with potentially significant toxic side effects. Patients undergoing therapy should be closely observed for signs of hematologic and nonhematologic toxicity. Periodic assessment of peripheral blood counts is recommended to detect the development of anemia, neutropenia and thrombocytopenia.

Tumor lysis syndrome associated with fludarabine treatment has been reported in CLL patients with large tumor burdens. Since fludarabine can induce a response as early as the first week of treatment, precautions should be taken in those patients at risk of developing this complication. 

There are inadequate data on dosing of patients with renal insufficiency. Fludarabine must be administered cautiously in patients with renal insufficiency. The total body clearance of 2-fluoro-ara-A has been shown to be directly correlated with creatinine clearance. Patients with moderate impairment of renal function (creatinine clearance 30 to 70 mL/min/1.73 m 2) should have their fludarabine dose reduced by 20% and be monitored closely. Fludarabine is not recommended for patients with severely impaired renal function (creatinine clearance less than 30 mL/min/1.73 m 2).
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as VIVLODEX. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue VIVLODEX and evaluate the patient immediately.
Betamethasone dipropionate spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during or after withdrawal of treatment. Factors that predispose to HPA axis suppression include the use of high-potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age.

Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test.

In a study including 48 evaluable subjects 18 years of age or older with moderate to severe plaque psoriasis, abnormal ACTH stimulation test results suggestive of adrenal suppression were identified in 5 out of 24 (20.8%) subjects after treatment with betamethasone dipropionate spray twice daily for 15 days. No subject (0 out of 24) had abnormal ACTH stimulation test results after treatment with betamethasone dipropionate spray twice daily for 29 days [see Clinical Pharmacology (12.2)].

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. If signs and symptoms of steroid withdrawal occur, supplemental systemic corticosteroids may be required.

Systemic effects of topical corticosteroids may also manifest as Cushing's syndrome, hyperglycemia, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids.

Minimize the unwanted risks from endocrine effects by mitigating the risk factors favoring increased systemic bioavailability and by using the product as recommended [see Dosage and Administration (2)].

Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios. Use of betamethasone dipropionate spray is not recommended in pediatric patients [see Use in Specific Populations (8.4)].
PURPOSE:To obtain the subject antibody used for the purification of a B type hepatitis vaccine produced from a yeast as a host by immunizing a vertebrate with the yeast or its fragment to prepare an astisera recognizing the yeast, and subsequently purifying the antisera to give an immunoglobulin fraction. CONSTITUTION:A yeast (e.g. Pichia pastoris) or its fragment as an antigen is intravenously injected into a vertebrate (e.g. rabbit) by the use of an injector for the immunization of the vertebrate. The same operation are repeated every three days after the first injection, and after 24 days, the whole blood of the rabbit is collected. The blood is centrifuged to give the serum, from which an antisera recognizing the yeast is prepared. The antisera is subjected to an ammonium sulfate fractionation treatment, and the obtained IgG fraction (immunoglobulin G) is applied to a column filled with a carrier bonded to protein A, etc. The adsorbed fraction is eluted to obtain the objective antibody specifically recognizing the yeast.
Concomitant chemoradiotherapy (CRT) is extensively used as primary organ preservation treatment for selected advanced laryngeal squamous cell carcinomas (LSCC). The oncologic outcomes of such regimens are comparable to those of total laryngectomy followed by adjuvant radiotherapy. However, the management of loco-regional recurrences after CRT remains a challenge, with salvage total laryngectomy being the only curative option. Furthermore, the decision whether to perform an elective neck dissection (END) in patients with rN0 necks, and the extent of the neck dissection in patients with rN + necks is still, a matter of debate. For rN0 patients, meta-analyses have reported occult metastasis rates ranging from 0 to 31 %, but no survival advantage for END. In addition, meta-analyses also showed a higher incidence of complications in patients who received an END. Therefore, END is not routinely recommended in addition to salvage laryngectomy. Although some evidence suggests a potential role of END for supraglottic and locally advanced cases, the decision to perform END should weigh benefits against potential complications. In rN + patients, several studies suggested that selective neck dissection (SND) is oncologically safe for patients with specific conditions: when lymph node metastases are not fixed and are absent at level IV or V. Super-selective neck dissection (SSND) may be an option when nodes are confined to one level. In conclusion, current evidence suggests that in rN0 necks routine END is not necessary and that in rN + necks with limited nodal recurrences SND or a SSND could be sufficient.
Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. The procedure will be performed bilaterally and 15 ml on each side, total 30 ml of 0.25% ropivacaine will be injected. After the procedure, a surgery scheduled will be proceeded. Patient of Control group will be proceeded the surgery after induction of anesthesia. All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively. If a patient complains pain more intense than VNRS 4 or demands an analgesic drug, a rescue analgesic would be allowed.
Phase IV, prospective, multicenter, randomized, double-blind, placebo-controlled, academically funded clinical trial, with 6 months follow-up. A total of 354 patients will be recruited. Inclusion criteria are: 1) successful surgical or percutaneous repair of a cardiac valve at least one year before screening and 2) persistent moderate or severe PH, and 3) absence of any residual significant valvular lesion. Patients will be randomized 1:1 to received sildenafil 40 mg t.i.d. or placebo. The primary endpoint is a clinical composite score combining: all-cause mortality, hospital admission for heart failure, World Health Organization (WHO) functional class, and the patient global assessment score. Additional clinical and mechanistic secondary end-points are defined.